More of the same in US 2022 – expect state moves and federal stalemate

Last year saw no movement on cannabinoid issues at federal level in the US, as CBD-Intel predicted, and it’s not looking too good for this year either – though some continued movement at state level on medical and recreational cannabis is expected at the least.

Overall our outlook on the regulation of cannabis in the US in 2021 provided more hits than misses. We correctly predicted that the Food and Drug Administration (FDA) would not make a legal pathway for CBD products in 2021 but we were slightly over-optimistic that Congress would pass some sort of federal cannabis reform.


Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Erik Galavis
+34 654 320 547
Email Erik

Pablo Sharrock
+34 722 642 678
Email Pablo